Retrospective analysis of patients with stage IV NSCLC and high PD‐L1 expression (tumor proportional score/TPS ≥ 50%), receiving first‐line therapy with pembrolizumab alone or in combination with chemotherapy at the West German Cancer Center from 2017 to 2022. This evidence concerns the gene CD274 and neoplasm.